Prognostic factors for the low-grade glioma that are well known include IDH mutations (Batsios et al., 2019; Ye et al., 2019), 1p/19q co-deficiency (Zhang et al., 2019a), ATRX mutation (Ren et al., 2019), TERT promoter mutations (Chan et al., 2015), CIC loss (Sahm et al., 2012), FUBP1 loss (Sahm et al., 2012) and PTEN loss (Sabha et al., 2014) and the above prognostic marker contribute to clinicians to understand the mechanism of low-grade gliomas. This evidence concerns the gene ATRX and glioma.